A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices

A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Research Center at The Institute of Cancer Research, London (ICR) and the Breast Cancer Now Research Unit at King's College London, have uncovered a new weakness in triple negative breast cancer linked to a gene called HORMAD1 and a way to target it.